Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Freeline Therapeutics Holdings plc

Freeline is a clinical-stage biotechnology company focused on developing transformative gene therapies for chronic debilitating diseases. Freeline uses its proprietary, rationally designed AAV vector and capsid (AAVS3), along with novel promoters and transgenes, to deliver a functional copy of a therapeutic gene into human liver cells, thereby expressing a persistent functional level of the missing or dysfunctional protein into a patient’s bloodstream. The company is currently advancing FLT201, a highly differentiated gene therapy candidate that delivers a novel transgene, in a Phase 1/2 clinical trial in people with Gaucher disease type 1. Freeline has additional programs in research, including one focused on GBA1-linked Parkinson’s disease that leverages the same novel transgene as FLT201. Freeline is headquartered in the UK and has operations in the United States.

Freeline

Today, on the start of #BlackHistoryMonth, our Chief People Officer Nicole Jones, SPHR reflects on the contributions of Black leaders and recognizes those in her own life who have supported her career.
 
Throughout the month, we look forward to celebrating the rich cultural heritage of the Black community and recognizing their triumphs in the face of adversity.

#MLKDay is an opportunity for us to honor the legacy of Dr. Martin Luther King Jr. and reflect on how we can carry his legacy forward.
 
This year, The King Center’s theme is “It Starts With Me.”
 
Today and every day, we have the opportunity to embrace Dr. King’s values by opening our hearts and minds, showing courage and compassion, and being steadfast in our pursuit for a kinder, more equitable and peaceful world.

From virtual meetups to in-person team dinners, our employees across the UK and US enjoyed some holiday festivities and fun this month!
 
Our virtual “speed networking” event gave employees across our sites a chance to connect socially in smaller groups, as we continue to foster a strong, collaborative, and united culture.
 
This holiday season and new year, we want to extend a special thanks to the patient advocacy groups and Gaucher community who continue to show resilience and support for one another, as well as for the hard work and dedication of our entire team.
 
From all of us at Freeline, we wish you a happy holiday and great start to the new year!

Join us Wednesday, November 29, for an educational webinar on two #Gaucher disease type 1 gene therapy trials currently enrolling participants including our Phase 1/2 GALILEO-1 study.
 
We look forward to discussing these opportunities alongside Prevail Therapeutics and in partnership with the Gaucher Community Alliance and International Gaucher Alliance.
 
Register here: https://lnkd.in/gi73XstY

This week we express our gratitude for our Freeline team and their commitment to science and innovation, and to the Gaucher community whose resiliency continues to inspire our work day in and day out.
 
We hope everyone has a safe and happy Thanksgiving holiday!

Last week Aviva Rosenberg, JD,  co-founder and co-president of the Gaucher Community Alliance joined us to share her perspective on the importance of raising awareness of #gaucherdisease.

Thank you, Aviva, for your time and thoughtful insights!

#rarediseaseawareness

This week, Freeline employees from across the UK and US participated in our first Global Day of Service.
 
- Our teammates in Stevenage sorted, counted and boxed nearly 8,000 books for Kenyan libraries at Just be a Child.
 
- The Boston team volunteered at Community Servings, where they helped prep medically tailored, scratch-made meals for approximately 2,400 chronically and critically ill individuals.
 
- Our employees in New York volunteered at GMHC where they assisted clients and served nearly 180 hot meals.
 
Thank you to all who participated and helped to support our local communities!

That’s a wrap on #ESGCT2023! Thank you to the conference organizers and those attended our oral presentation.

#gaucherdisease

Today Freeline will share new clinical data from its Phase 1/2 clinical trial evaluating FLT201, its novel AAV #genetherapy candidate for #gaucher disease in an oral presentation at the European Society of Gene and Cell Therapy’s annual congress.

Learn more about the study here: https://lnkd.in/gaUunUbv

#ESGCT2023

Gaucher disease is a rare, inherited disorder that can cause debilitating and chronic symptoms for patients.

This #GaucherAwarenessMonth, we’re committed to raising awareness of the burden of the disease and the need for new treatment options. 

#gaucher #gaucherawareness #rarediseases #rarediseaseawareness

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22
net income	-33.28M -	-53.91M 61.97%	-96.32M 78.68%	-140.39M 45.75%	-88.97M 36.63%
depreciation and amortization	970K -	1.54M 58.76%	1.91M 24.22%	2.39M 24.93%	1.74M 27.15%
deferred income tax		-4.56M -	-158K 96.53%	-171K 8.23%	-156K 8.77%
stock based compensation	114K -	1.46M 1,179.82%	6.20M 325.22%	10.72M 72.84%	5.08M 52.65%
change in working capital	6.43M -	-1.41M 121.97%	-6.68M 372.95%	19.74M 395.66%	9.07M 54.08%
accounts receivables	54K -		-91K -	98K 207.69%
inventory
accounts payables	7.53M -	4.13M 45.07%	1.54M 62.76%	-2.89M 287.66%	5.45M 288.44%
other working capital	-1.16M -	-5.55M 379.84%	-8.13M 46.51%	22.54M 377.30%	3.62M 83.93%
other non cash items		4.56M -	76K 98.33%	148K 94.74%	-4.98M 3,465.54%
net cash provided by operating activities	-25.77M -	-52.32M 103.01%	-94.97M 81.50%	-107.56M 13.26%	-78.22M 27.27%
investments in property plant and equipment	-3.75M -	-3.02M 19.39%	-2.51M 16.81%	-4.27M 70.01%	-7.01M 64.11%
acquisitions net			126.98K -
purchases of investments
sales maturities of investments
other investing activites			-980 -
net cash used for investing activites	-3.75M -	-3.02M 19.39%	-2.39M 20.98%	-4.27M 78.98%	-7.01M 64.11%
debt repayment
common stock issued			161.76M -	178.98K 99.89%	27.33M 15,168.92%
common stock repurchased
dividends paid
other financing activites	38.13M -	114.59M 200.49%	80.86M 29.43%	-1.16M 101.44%	195K 116.77%
net cash used provided by financing activities	38.13M -	114.59M 200.49%	242.62M 111.73%	-984K 100.41%	27.52M 2,897.05%
effect of forex changes on cash	-812K -	-1.01M 24.88%	11.74M 1,257.59%	302K 97.43%	-12.44M 4,219.87%
net change in cash	7.80M -	58.23M 646.55%	157.00M 169.62%	-112.51M 171.66%	-70.46M 37.38%
cash at beginning of period	8.54M -	16.34M 91.33%	74.57M 356.37%	231.58M 210.54%	119.06M 48.59%
cash at end of period	16.34M -	74.57M 356.37%	231.58M 210.54%	119.06M 48.59%	48.61M 59.18%
operating cash flow	-25.77M -	-52.32M 103.01%	-94.97M 81.50%	-107.56M 13.26%	-78.22M 27.27%
capital expenditure	-3.75M -	-3.02M 19.39%	-2.51M 16.81%	-4.27M 70.01%	-7.01M 64.11%
free cash flow	-29.52M -	-55.34M 87.47%	-97.48M 76.13%	-111.83M 14.72%	-85.24M 23.78%

LIFE:FREELINE

Freeline

Last Close

6.48

16/02 20:37

Market Cap

28.28M

Beta: -

Volume Today

5.35K

Avg: -

Preview